RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Mar. 12, 2025 |
Mar. 05, 2025 |
Dec. 01, 2023 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
Aug. 31, 2024 |
|
| Related Party Transaction [Line Items] | |||||||||
| Research and development expense | $ 704,000 | $ 952,000 | $ 1,677,000 | $ 1,858,000 | |||||
| Current liability | 4,098,000 | 4,098,000 | $ 5,468,000 | ||||||
| Converted into units | 1 | ||||||||
| Warrants per share | $ 2.25 | $ 2.25 | $ 1.25 | ||||||
| Common stock issued under Equity Line of Credit Agreement, net of issuance costs, shares | 200,000 | ||||||||
| Biodesix Inc [Member] | |||||||||
| Related Party Transaction [Line Items] | |||||||||
| Ownership percentage | 10.00% | ||||||||
| Biodesix Agreement [Member] | |||||||||
| Related Party Transaction [Line Items] | |||||||||
| Research and development expense | $ 125,000 | ||||||||
| Current liability | $ 0 | $ 0 | |||||||
| Biodesix Agreement [Member] | Biodesix Inc [Member] | |||||||||
| Related Party Transaction [Line Items] | |||||||||
| Ownership percentage | 5.00% | ||||||||
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|